Next&Bio, CSI Singapore to Co-Develop Cancer Organoid Precision Medicine

Next&Bio, a company specializing in organoid-based precision medicine, says it signed a memorandum of understanding with the Cancer Science Institute of Singapore (CSI Singapore) to develop novel precision medicines using cancer organoids.
[Korean Biomedical]
Press Release

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News